Trial Profile
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs LMP 744 (Primary)
- Indications Appendiceal cancer; Colorectal cancer; Lymphoma; Mesothelioma; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 13 Oct 2023 Status changed from recruiting to completed.
- 06 Jun 2023 Results (n=36) reporting safety and PK data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 26 Aug 2022 Planned End Date changed from 2 Oct 2022 to 2 Oct 2023.